Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBITDA: 2020-2023

Historic EBITDA for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.1 million.

  • Immuneering's EBITDA fell 14.90% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.4 million, marking a year-over-year decrease of 5.84%. This contributed to the annual value of -$53.4 million for FY2023, which is 5.84% down from last year.
  • Immuneering's EBITDA amounted to -$15.1 million in Q4 2023, which was down 19.88% from -$12.6 million recorded in Q3 2023.
  • Immuneering's EBITDA's 5-year high stood at -$3.2 million during Q2 2020, with a 5-year trough of -$15.1 million in Q4 2023.
  • Its 3-year average for EBITDA is -$11.5 million, with a median of -$12.4 million in 2023.
  • As far as peak fluctuations go, Immuneering's EBITDA slumped by 146.59% in 2021, and later grew by 1.70% in 2023.
  • Immuneering's EBITDA (Quarterly) stood at -$5.8 million in 2020, then tumbled by 85.55% to -$10.8 million in 2021, then decreased by 21.28% to -$13.1 million in 2022, then fell by 14.90% to -$15.1 million in 2023.
  • Its EBITDA was -$15.1 million in Q4 2023, compared to -$12.6 million in Q3 2023 and -$12.2 million in Q2 2023.